Introduction {#s1}
============

Until recently, the prevalence of asthma (Gershon et al., [@B28]; de Marco et al., [@B20]), rhinitis (Hansen et al., [@B33]), and atopic dermatitis (Duggan et al., [@B22]) has been increasing in many developed countries. This increase coincided with improved hygiene and socioeconomic conditions and with a decrease in the incidence of many infectious diseases (Bach, [@B5]) as well as with an increase in the consumption of fossil fuels (Shafiee and Topal, [@B74]). Although earlier researchers had proposed theories linking atopic disease and hygiene (Blackley, [@B8]; Leibowitz et al., [@B48]), in 1989 Strachan proposed a formal theory (i.e., the "hygiene hypothesis") based on studies of the relationship between hay fever and microbial infections in early childhood and adolescence in the United Kingdom (Strachan, [@B79]). In essence, the hypothesis holds that improved hygiene in early life reduces microbial exposures which were important in priming the immune response and were protective against atopic disorders. This hypothesis was subsequently expanded to cover asthma and autoimmune diseases (Okada et al., [@B63]).

*Helicobacter pylori* is a gram-negative spiral bacterium etiologically associated with both gastric and extragastric diseases including gastric cancer (Graham, [@B30]). Although the incidence and prevalence of *H. pylori* has markedly decreased in many developed countries, overall at least 50% of adults worldwide are infected (Leja et al., [@B49]). The infection is typically acquired in childhood. Because the increase in childhood atopic diseases appeared to correspond to a fall in *H. pylori* acquisition, it was suggested that the two conditions might be related. Several mechanisms were proposed to link the hygiene hypothesis with *H. pylori* infections (Cremonini and Gasbarrini, [@B18]; Shiotani et al., [@B76]). *H. pylori* infection is thought to influence the process of inducing naïve T cells in the two main functional groups: T helper 1 (Th1) and helper 2 (Th2) subsets. For example, T cells in the gastric mucosa of *H. pylori*-infected patients produce relatively more interferon-γ and relatively less IL-4 than is found in the gastric mucosa of uninfected individuals suggesting that that *H. pylori* may lead to a Th1-polarized immune response (Bamford et al., [@B6]; Sommer et al., [@B78]). Accordingly, *H. pylori* infection may also reduce the risk of asthma and allergy due to suppression of the Th2 response (Fox et al., [@B25]).

T-regulatory (Treg) cells are also increased in *H. pylori-*infected human gastric mucosa (Lundgren et al., [@B52]). Experiments in mice showed that the persistence of *H. pylori* was associated with reprograming of dendritic cell resulting in impairment of T-cells effector function, induction of mucosal T-reg cells and skewing of the immune response toward tolerance (Oertli et al., [@B62]). Two *H. pylori* antigens (γ-glutamyl transpeptidase and VacA) induced Treg cells in the mouse gastric mucosa resulting in development of tolerance and a reduction in allergic responses (Oertli et al., [@B61]). Of interest, induction of Treg in the gastric mucosa is also an important step in the establishment and maintenance of *H. pylori-*induced gastric adenocarcinoma (Kandulski et al., [@B41], [@B40]). Although animal studies clearly showed a relation between experimental *H. pylori* infection and protection from ovalbumin-induced asthma (Codolo et al., [@B15]; Arnold et al., [@B3]), the neonatal mouse model provides similar results with many different antigens other than those associated with *H. pylori* (Fujimura et al., [@B26]). Thus, while the results with neonatal mice are reproducible, the marked differences between the immune system of neonatal mice and humans suggest the need for great caution when trying to apply the lessons learned in neonatal mice to human disease (Renz et al., [@B68]).

Clinical studies in Taiwan have shown that mass eradication of *H. pylori* can remarkedly reduce the incidence of peptic ulcer, gastric cancer and gastric atrophy (Lee Y. C. et al., [@B45]). *H. pylori* eradication was also shown to reduce the risk of metachronous cancer after endoscopic treatment of primary gastric cancer (Yoon et al., [@B92]). While there is current interest in worldwide *H. pylori* eradication to reduce or eliminate gastric cancer (Graham and Uemura, [@B31]; Graham, [@B30]; Lee et al., [@B46]), it has been suggested that an eradication program might have untoward effects if *H. pylori* has a protective role against asthma and atopic diseases (Noverr et al., [@B59]).

Although most *H. pylori* infections are asymptomatic about 20% eventuate in a potentially life threatening clinical disease. The fact that progressive gastric damage is often silent has suggested to some that the bacterium may be harmless, commensal, or even beneficial (Carroll et al., [@B12]; Mishra, [@B57]). We collected data from PubMed using keyword combination *H. pylori* (*pylori* or *Helicobacter*) with atopy (atopy or atopic disease or atopic dermatitis), allergy (allergy, allergic disease, allergic rhinitis) and asthma for articles published through March 2016. We excluded abstracts alone or unpublished articles. Here, we summarize the controversies surrounding the role of gastric *H. pylori* colonization as protective against atopy, allergy, and asthma or whether the presence of *H. pylori* is primarily that of a biomarker for poor hygiene.

Association between *H. pylori* infection and atopy, allergy, and asthma {#s2}
========================================================================

Positive studies
----------------

Surveys in Europe, America, and Asia have reported an inverse relationship between *H. pylori* infection and atopy, allergy, and asthma (Kosunen et al., [@B42]; Chen and Blaser, [@B13]; Shiotani et al., [@B76]). Two cross-sectional studies have been based on National Health and Nutrition Examination Surveys in the United States (Chen and Blaser, [@B13], [@B14]) (Table [1](#T1){ref-type="table"}). The initial study involved 7,412 adults (NHANES III) and reported that *H. pylori* infection was significantly and inversely associated with dermatitis, rash, and eczema in the last year leading up to the survey (OR 0.73; 95% CI 0.56--0.96). Similar trends were observed for asthma (OR 0.89; 95% CI 0.68--1.16) and wheezing (OR 0.73, 95% CI 0.57--0.94) (Chen and Blaser, [@B14]). Moreover, *H. pylori* was inversely associated with past (OR 0.69, 95% CI 0.45--1.06) or current bouts of asthma (OR 0.41, 95% CI 0.24--0.69), and with recent episodes of wheezing, allergic rhinitis, dermatitis, eczema, and rash (Chen and Blaser, [@B14]). The other survey of 7,663 adults (NHANES 1999--2000) with asthma, allergic rhinitis, and atopic disorder by the same group (Chen and Blaser, [@B13]) also revealed that antibody to the *H. pylori* cytotoxin-associated gene product (CagA), a marker of more inflammatory type of *H. pylori* infection, was inversely correlated with asthma (OR 0.79; 95% CI 0.63--0.99) and allergic rhinitis (OR 0.77; 95% CI 0.62--0.94), especially among those who developed these conditions in childhood (Table [1](#T1){ref-type="table"}; Study No. 10). Moreover, individuals (median age \<43 years) who tested positive for for CagA and *H. pylori* antibodies were less likely to have developed allergies in the last year leading up to the survey and were less likely to be sensitized to pollens and molds, compared to antibody negative individuals (Chen and Blaser, [@B13]). Based on these two studies, *H. pylori* infection was proposed to possibly be protective against asthma and allergy. A subsequent case-control study of 318 adults with asthma and 208 controls in New York (Reibman et al., [@B67]) also reported the presence of CagA antibody to be significantly and inversely correlated with asthma (OR 0.57, 95% CI = 0.36--0.89) after adjustment for age, race, and income. In addition, a survey in an adult population in the UK based on urea breath testing for active *H. pylori* infection found a 30% reduction in the risk of atopy (McCune et al., [@B55]). Finally, levels of IgE antibodies were found to be higher in adult Finnish individuals who also had *H. pylori* antibodies in 1994 but not in 1973 (Kosunen et al., [@B43]). Similar results were reported in Danish (Linneberg et al., [@B50]), Israeli (Zevit et al., [@B93]), Scandinavian (Janson et al., [@B36]), and Japanese (Shiotani et al., [@B76]) populations.

###### 

Association between *H. pylori* and atopy, allergy, and asthma in cross-sectional studies.

  **No**.   **Author**    **Year**   **Study period**   **Location**      **Mean age (range)**   ***H. pylori* diagnosis**   **Indicator**                                ***H. pylori* positive/Indicator positive (%)**    ***H. pylori* positive/Indicator negative (%)**     ***P*-value**
  --------- ------------- ---------- ------------------ ----------------- ---------------------- --------------------------- -------------------------------------------- -------------------------------------------------- --------------------------------------------------- ----------------------------------------
  1         Kosunen       2002       1973               Finland           (15--54)               IgG and IgA *H. pylori*     IgE                                          16/147 (10.9)                                      20/179 (11.2)[\#](#TN3){ref-type="table-fn"}        0.9340
                                     1994                                                                                                                                 3/59 (5.1)[¶](#TN1){ref-type="table-fn"}           54/260 (20.8)[\#](#TN3){ref-type="table-fn"}        0.0095
  2         Linneberg     2003       1990--1991         Denmark           (15--69)               IgG *H. pylori*             IgE                                          75/273 (27.5)[¶](#TN1){ref-type="table-fn"}        323/824 (39.2)[\#](#TN3){ref-type="table-fn"}       \<0.001[¶¶](#TN2){ref-type="table-fn"}
                                                                                                                             Allergic rhinitis by questionnaire           48/271 (17.7)[¶](#TN1){ref-type="table-fn"}        236/822 (28.7)[\#](#TN3){ref-type="table-fn"}       \<0.001[¶¶](#TN2){ref-type="table-fn"}
  3         Cullinan      2003       1198--1999         England           28                     IgG *H. pylori*             Skin prick test                              53/151 (35.0)[¶](#TN1){ref-type="table-fn"}        278/745 (37.0)[\#](#TN3){ref-type="table-fn"}       0.52
  4         McCune        2003       N/A                England           (20--59)               Urea breath test            Atopy by questionnaire                       85/1079 (7.9)[¶](#TN1){ref-type="table-fn"}        235/2165 (10.9)[\#](#TN3){ref-type="table-fn"}      0.007
  5         Jarvis        2004       1992--1993         England           (20--44)               IgG *H. pylori*             Wheeze by questionnaire                      60/208 (28.9)[¶](#TN1){ref-type="table-fn"}        167/613 (27.2)[\#](#TN3){ref-type="table-fn"}       0.64
                                                                                                                             Waking with cough by questionnaire           62/208 (30.0)[¶](#TN1){ref-type="table-fn"}        190/613 (31.0)[\#](#TN3){ref-type="table-fn"}       0.21
                                                                                                                             Hay fever by questionnaire                   60/208 (28.9)[¶](#TN1){ref-type="table-fn"}        181/613 (29.6)[\#](#TN3){ref-type="table-fn"}       0.95
                                                                                                                             IgE                                          83/208 (39.9)[¶](#TN1){ref-type="table-fn"}        230/613 (37.6)[\#](#TN3){ref-type="table-fn"}       0.43
  6         Radon         2004       2002               Germany           (18--44)               IgG *H. pylori*             IgE                                          18/91 (19.8)                                       50/230 (21.7)                                       0.814[¶¶](#TN2){ref-type="table-fn"}
  7         Pessi         2004       N/A                Finland           \>30                   IgG *H. pylori*             Asthma by physician                          115/245 (46.9)                                     205/405 (50.6)                                      0.370
  8         von Hertzen   2005       1997--1998         Finland           25--54                 IgG *H. pylori*             Skin prick test                              62/268 (23.1)                                      141/507 (27.8)                                      0.526
                                                        Russia            25--54                 IgG *H. pylori*             Skin prick test                              78/90 (86.5)                                       280/297 (94.3)                                      0.011
  9         Jun           2006       2005--2005         China             50.5                   IgG *H. pylori*             Chronic bronchitis                           40/46 (86.9)                                       29/48 (60.4)                                        \<0.01
  10        Chen          2007       1998--1994         United States     43.0                   IgG *H. pylori*             Self-reported asthma (current)               169/3,720 (4.5)[¶](#TN1){ref-type="table-fn"}      196/3,943 (5.0)[\#](#TN3){ref-type="table-fn"}      0.409[¶¶](#TN2){ref-type="table-fn"}
                                                                                                                             Self-reported asthma (lifetime)              229/3,720 (6.2)[¶](#TN1){ref-type="table-fn"}      296/3,943 (7.5)[\#](#TN3){ref-type="table-fn"}      0.022[¶¶](#TN2){ref-type="table-fn"}
                                                                                                                             Self-reported allergic rhinitis (current)    236/3,720 (6.3)[¶](#TN1){ref-type="table-fn"}      380/3,943 (9.6)[\#](#TN3){ref-type="table-fn"}      \<0.001[¶¶](#TN2){ref-type="table-fn"}
                                                                                                                             Self-reported allergic rhinitis (lifetime)   278/3,720 (7.5)[¶](#TN1){ref-type="table-fn"}      439/3,943 (11.1)[\#](#TN3){ref-type="table-fn"}     \<0.001[¶¶](#TN2){ref-type="table-fn"}
                                                                                                                             Self-reported allergic symptoms              1,935/3,720 (52.0)[¶](#TN1){ref-type="table-fn"}   2,398/3,943 (60.8)[\#](#TN3){ref-type="table-fn"}   \<0.001[¶¶](#TN2){ref-type="table-fn"}
  11        Seiskari      2007       1994, 1997--1999   Finland, Russia   11.4 (7--15)           IgG *H. pylori*             IgE                                          9/194 (4.6)[¶](#TN1){ref-type="table-fn"}          8/72 (11.1)[\#](#TN3){ref-type="table-fn"}          0.055
  12        Chen          2008       1999--2000         United States     (14--49)               IgG *H. pylori*             Asthma by questionnaire (ever)               267/2,625 (10.2)[¶](#TN1){ref-type="table-fn"}     679/4,787 (14.2)[\#](#TN3){ref-type="table-fn"}     0.05
                                                                                                                             Dermatitis, eczema, rash by questionnaire    234/2,625 (8.9)[¶](#TN1){ref-type="table-fn"}      514/4,787 (10.7)[\#](#TN3){ref-type="table-fn"}     0.014[¶¶](#TN2){ref-type="table-fn"}
                                                                                                                             Wheeze by questionnaire                      275/2,625 (10.5)                                   653/4,787 (13.6)[\#](#TN3){ref-type="table-fn"}     \<0.001[¶¶](#TN2){ref-type="table-fn"}
                                                                          (3--19)                IgG *H. pylori*             Allergic rhinitis by questionnaire           62/750 (8.3)[¶](#TN1){ref-type="table-fn"}         275/2,577 (10.7)[\#](#TN3){ref-type="table-fn"}     0.02
                                                                                                                             Asthma by questionnaire (current)            66/750 (8.8)[¶](#TN1){ref-type="table-fn"}         253/2,577 (9.8)[\#](#TN3){ref-type="table-fn"}      0.03
                                                                                                                             Asthma by questionnaire (ever)               98/750 (13.1)[¶](#TN1){ref-type="table-fn"}        409/2,577 (15.9)[\#](#TN3){ref-type="table-fn"}     0.15
                                                                                                                             Allergic rhinitis and asthma (ever)          14/750 (1.9)[¶](#TN1){ref-type="table-fn"}         81/2,577 (3.1)[\#](#TN3){ref-type="table-fn"}       0.99
  13        Baccioglu     2008       N/A                Turkey            38.0 (17--74)          Histopathology              Skin prick test                              20/74 (27.0)[¶](#TN1){ref-type="table-fn"}         4/16 (25.0)[\#](#TN3){ref-type="table-fn"}          0.86
                                                                                                                             Asthma by physician                          8/74 (10.8)[¶](#TN1){ref-type="table-fn"}          5/16 (31.3)[\#](#TN3){ref-type="table-fn"}          0.03
                                                                                                                             Rhinitis                                     45/74 (60.8)[¶](#TN1){ref-type="table-fn"}         11/16 (68.8)[\#](#TN3){ref-type="table-fn"}         0.77
                                                                                                                             Urticaria                                    20/74 (27.0)[¶](#TN1){ref-type="table-fn"}         6/16 (37.5)[\#](#TN3){ref-type="table-fn"}          0.54
                                                                                                                             Food allergy                                 9/74 (12.2)[¶](#TN1){ref-type="table-fn"}          1/16 (6.3)[\#](#TN3){ref-type="table-fn"}           0.49
  14        Fullerton     2009       1991               England           (18--71)               IgG *H. pylori*             Skin prick test                              162/643 (25.2)[¶](#TN1){ref-type="table-fn"}       552/1,732 (31.9)[\#](#TN3){ref-type="table-fn"}     0.002[¶¶](#TN2){ref-type="table-fn"}
                                                                                                                             Hay fever                                    143/643 (22.2)[¶](#TN1){ref-type="table-fn"}       455/1,732 (26.3)[\#](#TN3){ref-type="table-fn"}     0.05[¶¶](#TN2){ref-type="table-fn"}
                                                                                                                             Chronic bronchitis                           107/643 (16.6)[¶](#TN1){ref-type="table-fn"}       208/1,732 (12.0)[\#](#TN3){ref-type="table-fn"}     0.004[¶¶](#TN2){ref-type="table-fn"}
                                                                                                                             Asthma by physician                          62/643 (9.6)[¶](#TN1){ref-type="table-fn"}         151/1,732 (8.7)[\#](#TN3){ref-type="table-fn"}      0.536[¶¶](#TN2){ref-type="table-fn"}
  15        Zevit         2012       2007--2008         Israel            (5--18)                Urea breath test            Asthma by physician                          233/3,175 (7.3)[¶](#TN1){ref-type="table-fn"}      345/3,784 (9.1)[\#](#TN3){ref-type="table-fn"}      0.007
  16        Karimi        2013       2010--2011         Iran              (6--12)                Urea breath test            Asthma by physician                          18/98 (18.4)                                       23/98 (23.4)                                        0.380
  17        Lee           2014       2010--2013         Korean            55.4                   IgG *H. pylori*             Asthma by questionnaire and IgE              225/320 (70.3)                                     1,159/1,794 (64.6)                                  0.667[¶¶](#TN2){ref-type="table-fn"}
  18        Hollander     2016       2002--2006         Netherland        6                      IgG *H. pylori*             Wheezing by questionnaire                    18/269 (6.7)                                       231/2,866 (8.1)                                     0.24
                                                                                                                             Asthma by questionnaire                      23/198 (11.6)                                      219/2,864 (7.6)                                     0.045
                                                                                                                             Eczema by questionnaire                      59/610 (9.7)                                       189/2,472 (7.6)                                     0.25
  19        Lim           2016       2011               South Korea       ≥18                    IgG *H. pylori*             Asthma by physician, questionnaire           229/9,492 (2.4)[¶](#TN1){ref-type="table-fn"}      130/5,540 (2.3)[\#](#TN3){ref-type="table-fn"}      0.333[¶¶](#TN2){ref-type="table-fn"}

Atopy, allergy, or asthma positive/H. pylori positive;

*Atopy, allergy, or asthma positive/H. pylori negative*.

*When authors did not provide P-values, we calculated them using SigmaStat version 3.5 (Systat Software, Inc., Richmond, CA)*.

Negative studies
----------------

Contradictory results include a study in which *H. pylori* failed to protect Finnish siblings equally from atopic sensitivity (53/151, 35% vs. 278/745, 37%, *P* = 0.52) (Cullinan et al., [@B19]). Higher IgE antibodies were not associated with *H. pylori* antibodies in Germans (Radon et al., [@B65]). A survey of 240 atopic patients and 240 controls from a larger cohort of 1,659 Italians (Matricardi et al., [@B54]) (Table [2](#T2){ref-type="table"}) did not find significant associations, although the adjusted OR for atopy decreased along a gradient of exposure to *H. pylori* (35/240, 15% vs. 44/240, 18%, *P* = 0.325). A skin prick test for allergy also failed to discriminate between Turkish volunteers infected with or uninfected with *H. pylori* (Baccioglu et al., [@B4]), and between those with or without asthma (Annagur et al., [@B2]). *H. pylori* antibody prevalence was also higher in Chinese (Tsang et al., [@B83]) and Japanese (Jun et al., [@B38]) patients with asthma, but not significantly. In 1,211 subjects randomly selected from 15,000 British adults (Jarvis et al., [@B37]), the prevalence of cough and hay fever was similar in both infected and uninfected individuals (62/208, 30% vs. 190/613, 31%, *P* = 0.21 and 60/208, 28.9% vs. 181/613, 29.6%, *P* = 0.95, respectively). Wheezing (*P* = 0.64) and allergen-specific serum IgE (*P* = 0.43) were also higher in *H. pylori-*seropositive adults, but not statistically. Based on this study Jarvis et al. ([@B37]) concluded that the evidence did not link *H. pylori* to cough, hay fever, and wheezing. A survey in China also showed that *H. pylori* and CagA IgG antibodies were more prevalent in patients with chronic bronchitis than in controls (Jun et al., [@B39]). Finally, a 30-year nested case-control study of 113 participants with adult-onset wheezing and 267 controls in Scotland (Bodner et al., [@B9]) (Table [2](#T2){ref-type="table"}) found that atopic disorders were not significantly associated with *H. pylori* infection. The frequency of wheezing symptoms was comparable between groups, and was weakly but positively correlated with *H. pylori* antibodies. Furthermore, chronic cough and phlegm were more likely to be reported in *H. pylori* seropositive volunteers (6/19, 23.1%) than in seronegative participants (18/150, 12%, *P* ≤ 0.05). The latest studies also showed the contradictory that subjects with past *H. pylori* infection had significantly a highest prevalence of allergy based on IgE status (Lee et al., [@B44]) and a higher prevalence recent astma in *H. pylori* positive than *H. pylori* negative children (den Hollander et al., [@B21]).

###### 

Association between *H. pylori* and atopy, allergy, and asthma in case-control studies.

  **No**.   **Author**   **Year**   **Study period**   **Location**               **Mean age (range)**   ***H. pylori* diagnosis**   **Indicator**              ***H. pylori* positive/Indicator positive (%)**   ***H. pylori* positive/Indicator negative (%)**   ***P*-value**
  --------- ------------ ---------- ------------------ -------------------------- ---------------------- --------------------------- -------------------------- ------------------------------------------------- ------------------------------------------------- --------------------------------------
  1         Matricardi   2000       1990--1991         Italy                      (17--24)               IgG *H. pylori*             IgE                        35/240 (15.0)                                     44/240 (18.0)                                     0.325
  2         Bodner       2000       1995               Scotland                   (39--45)               IgG *H. pylori*             IgE                        77/150 (51.3)                                     65/125 (52.0)                                     0.991[¶¶](#TN4){ref-type="table-fn"}
                                                                                                                                     Wheeze                     49/85 (57.6)                                      93/190 (48.9)                                     0.229[¶¶](#TN4){ref-type="table-fn"}
                                                                                                                                     Chronic cough and phlegm   6/19 (23.1)                                       18/150 (12.0)                                     0.05
  3         Tsang        2000       1997--1998         Hong Kong                  42.6                   IgG *H. pylori*             Asthma by physician        44/90 (48.9)                                      37/97 (38.1)                                      0.30
  4         Jun          2005       2004--2005         Japan                      51.2                   IgG *H. pylori*             Asthma by physician        10/46 (21.7)                                      9/48 (18.8)                                       0.917[¶¶](#TN4){ref-type="table-fn"}
  5         Jaber        2006       2001--2003         Saudi Arabia               1 to ≥ 10              IgG *H. pylori*             Asthma by physician        45/220 (20.4)                                     128/543 (23.6)                                    0.36
  6         Annagur      2007       2003--2005         Turkey                     (5--15)                IgG *H. pylori*             Asthma by physician        20/79 (25.3)                                      6/36 (16.7)                                       0.227
  7         Janson       2007       1990--1994         Estonia, Iceland, Sweden   (20--44)               IgG *H. pylori*             IgE                        81/327 (24.8)                                     337/922 (36.6)                                    \<0.001
  8         Shiotani     2008       2005--2006         Japan                      19.5                   IgG *H. pylori*             Allergy by questionnaire   42/369 (11.4)                                     72/408 (17.6)                                     0.015
  9         Reibman      2008       N/A                United States              (18--65)               IgG *H. pylori*             Asthma by questionnaire    147/318 (46.2)                                    100/208 (48.1)                                    0.744[¶¶](#TN4){ref-type="table-fn"}

*When authors did not provide P-values, we calculated them using SigmaStat version 3.5 (Systat Software, Inc., Richmond, CA)*.

Cohort studies
--------------

Three cohort studies have been reported (Cam et al., [@B10]; Amberbir et al., [@B1]; Holster et al., [@B34]) (Table [3](#T3){ref-type="table"}). In one study, 74 children in Turkey were followed for 6 years and (Cam et al., [@B10]) found that atopy was less prevalent, but not significantly, in *H. pylori*-infected children (39.1 vs. 48.1%, *P* = 0.215). Similarly, a 3-year study on a cohort of Ethiopian children revealed that of 832 children infected with *H. pylori*, 235 (28.2%) did not experience hay fever, a prevalence that was not significantly lower than in uninfected children (18/44, 40.9%, *P* = 0.09). Similar trends were observed for wheezing. Nevertheless, borderline significant protection against eczema was noted (OR 0.49, 95% CI 0.24--1.01, *P* = 0.05). *H. pylori* was inconsistently associated with asthma and allergy in the third study and was not considered either beneficial or protective (Holster et al., [@B34]).

###### 

Association between *H. pylori* and atopic, allergy, and asthma in cohort studies.

  **No**.   **Author**   **Year**   **Study period**   **Location**   **Mean age (range)**   ***H. pylori* diagnosis**   **Indicator**                                 ***H. pylori* positive/Indicator positive (%)**   ***H. pylori* positive/Indicator negative (%)**   ***P*-value**
  --------- ------------ ---------- ------------------ -------------- ---------------------- --------------------------- --------------------------------------------- ------------------------------------------------- ------------------------------------------------- --------------------------------------
  1         Cam          2009       1999--2015         Turkey         14.8                   Urea breath test            Skin prick test                               15/47 (31.9)[¶](#TN5){ref-type="table-fn"}        13/27 (48.1)[\#](#TN6){ref-type="table-fn"}       0.215
                                                                                                                         Asthma by questionnaire                       4/47 (8.5)[¶](#TN5){ref-type="table-fn"}          1/27 (3.7)[\#](#TN6){ref-type="table-fn"}         0.646
                                                                                                                         Allergic rhinitis                             3/47 (6.4)[¶](#TN5){ref-type="table-fn"}          1/27 (3.7)[\#](#TN6){ref-type="table-fn"}         1.00
                                                                                                                         Atopic eczema                                 3/47 (6.4)[¶](#TN5){ref-type="table-fn"}          1/27 (3.7)[\#](#TN6){ref-type="table-fn"}         1.00
  2         Amberbir     2011       2005--2009         Ethiopia       3.0                    Stool antigen               Self-reported wheeze                          24/80 (30.0)                                      229/796 (28.8)                                    0.41
                                                                                                                         Self-reported eczema                          11/55 (20.0)                                      242/821 (29.5)                                    0.05
                                                                                                                         Self-reported hay fever                       18/44 (40.9)                                      235/832 (28.2)                                    0.09
                                                                                                                         Self-reported *D. pteronyssinus*              6/48 (12.5)                                       247/816 (30.3)                                    0.07
                                                                                                                         Self-reported cockroach                       6/36 (16.7)                                       247/828 (29.8)                                    0.29
  3         Holster      2012       1996--2004         Netherlands    (7--9)                 IgG *H. pylori*             Wheeze by questionnaire                       12/204 (5.9)                                      37/341 (10.9)                                     0.05
                                                                                                                         Allergic rhinitis by questionnaire            25/294 (8.5)                                      24/251 (9.6)                                      0.779[¶¶](#TN7){ref-type="table-fn"}
                                                                                                                         Atopic dermatitis by questionnaire            21/241 (8.7)                                      28/304 (9.2)                                      0.960[¶¶](#TN7){ref-type="table-fn"}
                                                                                                                         Physician-diagnosed asthma by questionnaire   7/98 (7.1)                                        42/447 (9.4)                                      0.609[¶¶](#TN7){ref-type="table-fn"}

Atopy, allergy, or asthma positive/H. pylori positive;

*Atopy, allergy, or asthma positive/H. pylori negative*.

*When authors did not provide P-values, we calculated them using SigmaStat version 3.5 (Systat Software, Inc., Richmond, CA)*.

*H. pylori* infection is significantly associated with drinking water, toilet type, location of residence, number of residents in a household, and birth order (Malaty et al., [@B53]; Nurgalieva et al., [@B60]; Ueda et al., [@B84]). These associations are well-demonstrated in a cross sectional study with two geographically contiguous cohorts of 266 Finnish and 266 Russian Karelian children living in markedly different cultures, economic systems, and standards of living (e.g., gross domestic product per capita US\$ 32,790 vs. US\$ 3,410) (Seiskari et al., [@B73]). These children were also surveyed for other microbes associated with poor hygiene, including hepatitis A virus, *Toxoplasma gondii*, and enterovirus. Importantly, antibodies against all microbes surveyed were higher in Russian Karelian children than in Finnish children. Conversely, allergen-specific IgE was higher in the latter than in the former, but allergy and atopy were not associated with *H. pylori* infection in Finnish children.

Meta-analyses
-------------

Because cohort studies were inconclusive as to whether *H. pylori* might either be protective or a surrogate for the hygiene hypothesis (Table [3](#T3){ref-type="table"}), meta-analyses were performed to increase the statistical power by critically appraising and synthesizing data from multiple studies (Goodman et al., [@B29]). Meta-analyses are available regarding a possible link between *H. pylori* infection and atopy (Lionetti et al., [@B51]; Taye et al., [@B82]) or asthma (Wang et al., [@B90], [@B89]; Zhou et al., [@B94]). Zhou et al. pooled data from 14 studies (28,283 patients) and found that *H. pylori* infection was significantly less frequent among volunteers with asthma than among controls (OR 0.84; 95% CI 0.73--0.96, *P* = 0.013) (Zhou et al., [@B94]). However, the differences were only significant in North America but not in the Asia and Europe or in a subanalysis related to positivity of CagA. Another meta-analysis noted a significant inverse association between *H. pylori* and asthma in both cross-sectional studies of 30,239 subjects (OR 0.84; 95% CI 0.74--0.96) and cohort studies of 1,235 subjects (OR 0.82; 95% CI 0.53--1.27). In case-control studies (2,544 subjects) there was a weak inverse association (OR 0.94; 95% CI 0.79--1.12) (Wang et al., [@B89]). An 18% reduction of the risk (OR 0.82; 95% CI 0.73--0.91, *P* = 0.01) for atopy was also observed among *H. pylori*-infected participants in a meta-analysis of 21,348 participants that combined various study designs (i.e., mixed analysis of cross sectional and cohort studies) (Taye et al., [@B82]). Of note, a meta-analysis of five case-control (1,555 participants) studies did not confirm an inverse (OR 1.01, 95% CI 0.82--1.24) between *H. pylori* and asthma (Wang et al., [@B90]). A meta-analysis that included asthma within the atopy/allergy cases found that allergy and atopy had a significant inverse association with *H. pylori* in 11 case-control studies of 4,607 participants (OR 0.80, 95% CI 0.62--0.97) whereas only allergy was inversely correlated in the cross-sectional studies of 14,198 participants (OR 0.74, 95% CI 0.65--1.16) (Lionetti et al., [@B51]).

These meta-analyses are not without problems as they generally aggregrated multiple heterogeneous conditions into a single group (i.e., different criteria for asthma diagnosis such as physicians vs. symptoms) and, except for few studies, used serological detection of *H. pylori*. Serology does allow one to differentiate between recent and past infections. In addition, the meta-analyses were designed to examine the association between a single agent, *H. pylori* with asthma, allergy and atopy without considering whether it was specifically involved or was acting as a weak surrogate for the hygiene hypothesis.

Prospective studies testing the protection hypothesis {#s3}
=====================================================

Overall, the prevalence of asthma appears to have increased earlier due in part to improvement in diagnostic and awareness. This increase now appears to have peaked and globally the prevalence of asthma has been reported to be decreasing or to have plateued (i.e., in Greece, Turkey, Scotlandia, and England) (Sears, [@B72]). For example, *H. pylori* infection has steadily decreased in England (Vyse et al., [@B88]) and if *H. pylori* were protective, one would expect the incidence of asthma to increase. However, asthma has decreased in all groups. particularly in children under 5 years (Simpson and Sheikh, [@B77]). Even more striking is the fact that those children least likely to have *H. pylori* (i.e., the higher socioeconomic class) experienced a greater fall in asthma incidence than seen in the lower socioeconomic classes (in which the prevalence also fell) (Graham, [@B30]).

The hypothesis that *H. pylori* is protective is based on improved hygiene which reduced *H. pylori* infections leading to increased risk. This hypothesis can be prospectively evaluated by examination of the prevalence of atopic/allergic disease in populations with low *H. pylori* prevalence but low incomes and hygienic standards. Such populations allow one to separate low prevalence of *H. pylori* infection from reduced hygiene and directly attempt to falsify the hypothesis that *H. pylori* provides the protective antigens responsible for protection against disease, in this case asthma.

There are a number of countries where *H. pylori* infections are rare despite poor living conditions (e.g., Malaysia, Indonesia, and Zanzibar) (Farag et al., [@B24]; Lee Y. Y. et al., [@B47]; Syam et al., [@B81]). For example, *H. pylori* infection is infrequent in Malaysia (Uyub et al., [@B85]; Sasidharan and Uyub, [@B71]) and thus one would expect a high rate of any disease against which *H. pylori* offered protection. However, wheezing due to asthma occurs in only 4.3% of Malaysian children 6--7 years old and 5.7% of those 13--14 years old. Allergic rhinitis in primary school is also rare (5%) (Quah et al., [@B64]) and asthma in the general population was noted to be relatively low in comparison to 56 other countries (Raj et al., [@B66]). In Indonesia (Figure [1](#F1){ref-type="fig"}), there was no an inverse correlation between the frequency of asthma and *H. pylori* infection: asthma affected 6.9% in Jakarta (*H. pylori* prevalence 3.2%) vs. 6.5% of the population in Manado (*H. pylori* prevalence 14%) (Sundaru, [@B80]; Syam et al., [@B81]). The prevalence of asthma is similar in Medan (11.6%), Makassar (11.2%), and Jakarta (10.7%) although the prevalence *H. pylori* infection is about 12 and 11 times higher in Medan and Makassar than Jakarta, and is about 28 and 23 times higher in Batak and Buginese than Javanese as the predominant ethnics in Medan, Makassar, and Jakarta, respectively (Sundaru, [@B80]; Syam et al., [@B81]). Thus, the original projections regarding asthma in countries with low *H. pylori* prevalence and relatively poor hygiene failed.

![*Helicobacter pylori* and asthma in Indonesia. The prevalence of asthma is almost similar in Medan, Makassar, and Jakarta although the prevalence *H. pylori* infection is higher in Medan and Makassar than Jakarta.](fmicb-08-01034-g0001){#F1}

The hygiene hypothesis and *H. pylori* infection {#s4}
================================================

The hygiene hypothesis suggests that environmental and microbial exposure can shape the developing immune system and confer protection or risk against subsequent immune-mediated disease (von Mutius, [@B87]). Accordingly, commensal saprophyte microflora or probiotic bacteria with various microbial antigens may have a role in reducing the individual risk of allergy (e.g., living or a farm or having a puppy) (Renz et al., [@B68]; Campbell et al., [@B11]). In both Estonia and Sweden, where the prevalence of allergy is widely different (Bjorksten et al., [@B7]), patients with allergy harbored less lactobacilli and bifidobacterium than controls, regardless of exposure to antibiotics. Of note, Estonian children with allergy harbored a higher number of aerobic microorganisms, especially coliforms, than *Staphylococcus aureus*, which was dominant in allergic Swedish children. However, another study reported that lactic acid bacteria and bifidobacterium were comparable between wheezing patients sensitized or not sensitized in childhood (Murray et al., [@B58]).

Sheikh and Strachan (Sheikh and Strachan, [@B75]) clarified that the hygiene hypothesis is "framed in conceptual rather than specific terms." Therefore, the protective effects of poor hygiene is likely due to synergism of multiple factors in the host and environment, rather than to a single agent (Vercelli, [@B86]). For example, adolescents who grow up on farms are less prone to asthma and allergic rhinitis than those who do not, possibly related to consumption of farm milk with higher concentrations of gram-negative bacteria and lipopolysaccharides (Riedler et al., [@B69]; Campbell et al., [@B11]). A recent meta-analysis across 14 countries (10,201 participants) also confirmed the role of the farm environment as a protective allergic risk and marker of microbial diversity for the inner city population (Campbell et al., [@B11]). Farms abound in microbial products, molds, and fungi and daily contact with these drive the maturation of immunity and reduce the risk of atopy and asthma (von Mutius, [@B87]). The prevention approach which was proposed as primary and secondary prevention of allergic diseases also emphasized not only a single agent, but multifactorial (i.e., hypoallergenic formula and reducing several allergens exposure) (Halken, [@B32]). Finally, it is also possible that protective events occur prior to childhood. For example, repeated pregnancy or intrauterine environment are associated with atopy (von Mutius, [@B87]).

Overall, allergy and asthma are considered multifactorial diseases triggered by interactions between the environment and host genes (McLeish and Turner, [@B56]). In general, allergic disorders are more prevalent in the northern than in the southern hemisphere, particularly in developed countries, in which rapid environmental changes in the last decades has led to increased outdoor and indoor pollution, climate change, and improved hygiene (Lionetti et al., [@B51]). Nonetheless, the hygiene hypothesis is not universally applicable, such as in the community with the lowest per capita income in New York. In this community, Afro-American and Hispanic-American children live in households with poor standards of living and hygiene, but exposure to various allergens and viruses paradoxically trigger asthma hospitalizations, with mortality rates more than five times higher than the national average (Webber et al., [@B91]; Garn and Renz, [@B27]).

Is *H. pylori* infection beneficial? {#s5}
====================================

The ancestor of *H. pylori* is believed to have established an ecological niche in the human stomach at least 100,000 years ago and then co-evolved with the host (Covacci et al., [@B17]). Nevertheless, its long history in the human stomach provides no information regarding whether *H. pylori* infection might be beneficial (Carroll et al., [@B12]; Mishra, [@B57]). For instance, hepatitis B virus is not considered commensal nor potentially beneficial, even though it accompanied humans from Africa 100,000--150,000 years ago (Robertson and Margolis, [@B70]). Hepatitis B infects one third of the global population, of whom more than 350 million are chronically infected. Like *H. pylori* the majority remain asymptomatic while the disease progresses with a small proportion presenting with complicated cirrhosis or hepatocellular carcinoma (El-Serag, [@B23]). Similarly, *Mycobacterium tuberculosis* continues to be a target of eradication even today, particularly in developing countries, even though it accompanied humans out of Africa, and caused deaths in one of five adults in Europe and North America between the 17 and 19th centuries (Comas et al., [@B16]). *H. pylori* is a primary cause peptic ulcers and gastric cancer (IARC, [@B35]).

Summary {#s6}
=======

*H. pylori* infection most likely acts as a weak surrogate for the presence of poor hygiene. The hypothesis that *H. pylori* or specific *H. pylori* antigens provide protective antigens reducing the frequence of atopy, allergy, or asthma is not supported by the current data and was falsified in experiments testing projections of the hypothesis. We conclude that *H. pylori* is a major human pathogen that causes progressive damage to the stomach. The infection is etiologically associated with chronic gastritis, peptic ulcer, and gastric malignancies, and should be eradicated.
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